<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271478</url>
  </required_header>
  <id_info>
    <org_study_id>FIS/IMSS/PROT/G09/739</org_study_id>
    <secondary_id>Registry CLIS</secondary_id>
    <nct_id>NCT01271478</nct_id>
  </id_info>
  <brief_title>Use of Telmisartan and Captopril in Inflammation of Hemodialysis Patients</brief_title>
  <official_title>Effect of Telmisartan and Captopril on Systemic Inflammation of Patients on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to compare the dual use of telmisartan and captopril vs the&#xD;
      individual use of such drugs and placebo on the systemic inflammation of patients on&#xD;
      hemodialysis (HD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once included, patients will be randomly allocated (by a computer-generated randomization&#xD;
      list) to one of the following groups: group 1 will receive Captopril, group 2 Telmisartan,&#xD;
      group 3 Captopril plus Telmisartan, and group 4 Placebo. Drugs will be provided as tablets&#xD;
      during a period of 3 months. All patients will have 3 HD sessions per week, with the same&#xD;
      kind of single-use dialysis membrane and dialysate Monthly visits will be scheduled for&#xD;
      clinical and biochemical evaluations. A blood sample will be taken at baseline and every&#xD;
      month for measurement of complete blood count, urea, creatinine, glucose, albumin, lipids,&#xD;
      and electrolytes (measured by usual methods). In serum samples at 0, 1 and 3 months, tumor&#xD;
      necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) concentrations will be measured by&#xD;
      ELISA using high sensitivity kits. Additionally, in the same serum samples, C-reactive&#xD;
      protein (CRP) concentrations will be measured by nephelometry using high sensitivity kits.&#xD;
      All laboratory measurements, including inflammation markers, will be performed in the Central&#xD;
      Laboratory (Hospital de Especialidades, Centro Médico Nacional de Occidente), by the same&#xD;
      personnel blinded to patient's details.&#xD;
&#xD;
      Treatment compliance will be recorded by counting tablets left in the container at the end of&#xD;
      each monthly visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 31, 2013</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentrations of TNF-a, IL-6 and CRP</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Inflammation</condition>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Telmisartan plus Captopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan plus Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day) plus 1 tablet of placebo orally twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Captopril plus Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients received captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets of placebo orally twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>captopril plus placebo</intervention_name>
    <description>This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day</description>
    <arm_group_label>Captopril plus Placebo</arm_group_label>
    <other_name>Capotena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan plus placebo</intervention_name>
    <description>Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day</description>
    <arm_group_label>Telmisartan plus Placebo</arm_group_label>
    <other_name>micardis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan plus Captopril</intervention_name>
    <description>Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)</description>
    <arm_group_label>Telmisartan plus Captopril</arm_group_label>
    <other_name>Capotena</other_name>
    <other_name>Micardis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in this group will receive 2 tablets of placebo (starch) twice a day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Starch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  ≥2 months on hemodialysis&#xD;
&#xD;
          -  Arteriovenous fistula as vascular access&#xD;
&#xD;
          -  Endorsement of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory cause of ESRD&#xD;
&#xD;
          -  Liver disease, cancer, AIDS&#xD;
&#xD;
          -  Any infectious disease 2 months before the study&#xD;
&#xD;
          -  Failed kidney graft&#xD;
&#xD;
          -  Hypersensitivity to angiotensin converting enzyme inhibitors or angiotensin receptor&#xD;
             blockers&#xD;
&#xD;
          -  Arterial hypotension&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Treatment with antibiotics, non-steroidal anti-inflammatory drugs, steroids,&#xD;
             immunosuppressives, statins, ACE inhibitors or ARB 3 months previous to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso M. M Cueto-Manzano, MD, MSc, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unidad de Investigación Médica en Enfermedades Renales, Hospital de Especialidades, CMNO, IMSS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Especialidades, CMNO, IMSS</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44320</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Ordaz-Medina SM, González-Plascencia J, Martín del Campo F, Rojas-Campos E, Montañez-Fernández JL, Espinoza-Gómez F, Cueto-Manzano AM. Is systemic inflammation of hemodialysis patients improved with the use of enalapril? Results of a randomized, double-blinded, placebo-controlled clinical trial. ASAIO J. 2010 Jan-Feb;56(1):37-41. doi: 10.1097/MAT.0b013e3181c1d830.</citation>
    <PMID>20051840</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Alfonso Martín Cueto Manzano</investigator_full_name>
    <investigator_title>Head, Medical Research Unit of Renal Diseases</investigator_title>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>telmisartan</keyword>
  <keyword>captopril</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Captopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

